LNWTC
VRTX icon

Laird Norton Wetherby Trust Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Laird Norton Wetherby Trust Company’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.73M Sell
11,528
-362
-3% -$160K 0.11% 133
2026
Q1 		$5.31M Buy
11,890
+133
+1% +$62K 0.12% 137
2025
Q4 		$5.33M Buy
+11,757
New +$5.07M 0.11% 149

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Laird Norton Wetherby Trust Company's VRTX Position: Q2 2026 in Review

Laird Norton Wetherby Trust Company reduced its Vertex Pharmaceuticals (VRTX) stake by 3% in Q2 2026, selling an estimated $160K and leaving 11,528 shares worth $5.73M. The position accounts for 0.11% of the portfolio, ranked #133.

Laird Norton Wetherby Trust Company first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Laird Norton Wetherby Trust Company held 11,528 shares of Vertex Pharmaceuticals worth $5.73M as of Q2 2026.
  • Laird Norton Wetherby Trust Company sold 362 Vertex Pharmaceuticals shares in Q2 2026, an estimated $160K.
  • Vertex Pharmaceuticals made up 0.11% of Laird Norton Wetherby Trust Company's portfolio in Q2 2026, its #133 holding.
  • Laird Norton Wetherby Trust Company first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Laird Norton Wetherby Trust Company's 13F filing for Q2 2026, filed 14 Aug 2026.